Sadar, Marianne

December 1, 2022

Portrait photo of Marianne Sadar

Dr.

Sadar, Marianne

BSc, PhD

e-mail:

msadar@bcgsc.ca

Lab Website

https://www.bcgsc.ca/labs/sadar-lab

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

BC Cancer Agency, Genome Science Centre

Location:

BC Cancer Agency

Short Bio

The major focus of Dr. Sadar’s research is to develop therapies that will delay or prevent tumour progression and emergence of hormone independence in prostate cancer.

  • Distinguished Scientist, Genome Sciences Centre, BC Cancer Agency
  • President, Society of Basic Urologic Research
  • Chief Scientific Officer, ESSA Pharma Inc
  • Professor, Pathology and Laboratory Medicine, University of British Columbia (UBC)

Academic
OpenClose

Academic Backgrounds

  • PhD, Biochemistry, University of Bradford, UK / University of Göteborg, Sweden.  1995
  • BSc, Biochemistry, Simon Fraser University. 1988

Awards & Recognition

  • SWIU/SBUR Award for Excellence in Urologic Research, First non-American to receive SWIU/SBUR Award for Excellence in Urologic Research, 2010
  • SFU Outstanding Alumni Award for Academic Achievement, Simon Fraser University, In recognition of significant achievements in cancer research, 2009
  • Terry Fox Young Investigator Award, National Cancer Instituate of Canada, 2008. The Terry Fox Young Investigator Award is a national award given annually to one investigator in the first 10 years of his/her career that is doing outstanding basic laboratory work in cancer.
  • Co-op recognition Award, University of British Columbia.  2003

Selected Publications

  • Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013 Jul 1;123(7):2948-60.
  • Yang YC, Meimetis LG, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD. Spongian diterpenoids inhibit androgen receptor activity. Mol Cancer Ther. 2013 May;12(5):621-31.
  • Myung JK, Sadar MD. Large scale phosphoproteome analysis of LNCaP human prostate cancer cells. Mol Biosyst. 2012 Aug;8(8):2174-82.
  • Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, Tien AH, Fernandez JG, de Voogd NJ, Sadar MD, Andersen RJ. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J Med Chem. 2012 Jan 12;55(1):503-14.
  • Haile S, Lal A, Myung JK, Sadar MD. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS One. 2011;6(9):e24197.
  • Sadar MD. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World J Urol. 2012 Jun;30(3):311-8.
  • Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011 Dec;68(24):3971-81.
  • Sadar MD. Small molecule inhibitors targeting the “achilles’ heel” of androgen receptor activity. Cancer Res. 2011 Feb 15;71(4):1208-13.
  • Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics. 2010 Sep 24;3:43.
  • Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire JA, Wang Y. Development of metastatic and non-metastatic tumor lines from a patient’s prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. Prostate. 2010 Nov 1;70(15):1636-44.
  • Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Bañuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010 Jun 15;17(6):535-46.
  • Chiu HH, Yong TM, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, Sadar MD. Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. Cancer Lett. 2010 Jun 28;292(2):176-85. doi: 10.1016/j.canlet.2009.11.023.
Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

  • Steroid receptor biochemistry
  • Drug development
  • Prostate cancer research
Teaching
OpenClose

Teaching